6 Bibliography

1. Park, K., Shalaby, W.S.W., and Park, H., *Controlled release drug delivery systems.*, in *Biodegradable hydrogels for drug delivery*, Technomic publishing company, I, Editor. 1993, Technomic publishing company, Inc.: Lancaster. p. 1 - 12.
2. Park, K., Shalaby, W.S.W., and Park, H., *Biodegradation*, in *Biodegradable hydrogels for drug delivery*, Technomic publishing company, I, Editor. 1993, Technomic publishing company, Inc: Lancaster. p. 13 - 34.
3. Nitsch, M.J., and Banakar, U.V., *Implantable drug delivery*, in *Advances in controlled delivery of drugs.*, Technomic publishing company, I, Editor. 1994, Technomic publishing company, Inc.Tech: Lancaster. p. 21 - 58.
4. Park, K., Shalaby, W.S.W., and Park, H., *Biodegradable drug delivery systems*, in *Biodegradable hydrogels for drug delivery*, Technomic publishing company, I, Editor. 1993, Technomic publishing company, Inc.: Lancaster. p. 189 - 232.
5. Jain, R.A., *The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices.* Biomaterials, 2000. 21: p. 2475-2490.
6. Floy, B.J., Visor, G.C., and Sanders, L.M., *Design of Biodegradable Polymer systems for Controlled Release of Bioactive Agents*, in *Polymeric Delivery Systems*, El-Nokaly, M A, Piatt, D M, and Charpentier, B A, Editors. 1993, American Chemical Society: Washington, DC. p. 154 - 167.
7. Lewis, D.H., *Controlled Release of Bioactive Agents from Lactide/Glycolide Polymers*, in *Biodegradable Polymers as Drug Delivery Systems*, Chasin, M, and Langer, R, Editors. 1990, Marcel Dekker: New York. p. 1 - 41.
8. Vert, M., Schwach, G., Engel, R., and Coudane, J., *Something new in the field of PLA/GA bioresorbable polymers?* Journal of Controlled Release, 1998. 53: p. 85 - 92.
9. Jalil, R., and Nixon, J.R., *Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: problems associated with preparative techniques and release properties.* Journal of Microencapsulation, 1990. 7(3): p. 297 - 325.

10. Boehringer, I., *Production Properties and Application of Biodegradable Polymers and Copolymers based on Lactic acid and Glycolic acid.* 1987.
11. Griffith, L.G., *Polymeric biomaterials.* Acta Materialia, 2000. 48: p. 263 - 277.
12. Middleton, J.C., and Tipton, A.J., *Synthetic biodegradable polymers as medical devices.* Birmingham polymers, Inc., 1998. 5(2).
13. Brophy, M.R., and Deasy, P.B., *Biodegradable Polyesters Polymers as Drug Carriers*, in *Encyclopedia of Pharmaceutical Technology*, Swarbrick, J, and Boylan, J C, Editors. 2001, Marcel Dekker, Inc.: New York. p. 1 - 25.
14. *Technical information. Physical properties of selected polymers*, Birmingham Polymers.
15. Hausberger, A.G., and De Luca, P., *Characterization of biodegradable poly(D,L-lactide-co-glycolide) polymers and microspheres.* Journal of Pharmaceutical & Biomedical Analysis, 1995. 13(6): p. 747-760.
16. Braybrook, J.H., *Polymers: Medicinal and Pharmaceutical.*, in *Encyclopedia of Pharmaceutical Technology*, Swarbrick, J, and Boylan, J C, Editors. 1995, Marcel Dekker: New York. p. 265 - 304.
17. Konan, Y., Gurny, R., and Allémann, E., *Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles.* International Journal of Pharmaceutics, 2002. 233: p. 239-252.
18. Angelova, N., and Hunkeler, D., *Rationalizing the design of polymeric biomaterials.* Trends in Biotechnology, 1999. 17: p. 409 - 421.
19. Montanari, L., Cilurzo, F., Selmin, F., Conti, B., Genta, I., Poletti, G., Orsini, F., and Valvo, L., *Poly(lactide-co-glycolide) microspheres containing bupivacaine: comparison between gamma and beta irradiation effects.* Journal of Controlled Release, 2003. 90: p. 281-290.
20. Uchegbu, I.F., *Parenteral drug delivery:2.* Pharmaceutical Journal, 1999. 263(7061): p. 355 - 358.
21. Bhagat, H.R., and Lange, R.S., *Implants and Implantation Therapy*, in *Encyclopedia of Pharmaceutical Technology*, Swarbrick, J, and Boylan, J C, Editors. 1993, Marcel Dekker: New York. p. 53 - 80.
22. Yamakawa, I., Kawahara, M., Watanabe, S., and Miyake, Y., *Sustained release of insulin by double-layered implant using poly(D,L-Lactic acid).* Journal of Pharmaceutical Sciences, 1990. 79(6): p. 505-509.

23. Qian, F., Szymansky, A., and Gao, J., *Fabrication and characterization of controlled release poly(D,L-lactide-co-glycolide) millirods.* Journal of Biomedical Materials Research, 2001. 55: p. 512 - 522.
24. Qian, F., Saidel, G.M., Sutton, D.M., Exner, A., and Gao, J., *Combined modeling and experimental approach for the development of dual-release polymer millirods.* Journal of Controlled Release, 2002. 83: p. 427-435.
25. Bodmer, D., Kissel, T., and Traechslin, E., *Factors influencing the release of peptides and proteins from biodegradable parenteral depot systems.* Journal of Controlled Release, 1992. 21: p. 129-138.
26. Bhardwaj, R., and Blanchard, J., *In vitro evaluation of poly/D,L-lactide-co-glycolide) polymer-based implants containing the alpha-melanocyte stimulating hormone analog, Melanotan-I.* Journal of Controlled Release, 1997. 45: p. 49 - 55.
27. Sanders, L.M., Kell, B.A., Mcrae, G.I., and Whitehead, G.W., *Prolonged controlled-release of Nafarelin, a luteinizing hormone-releasing hormone analogue, from biodegradable polymeric implants: Influence of composition and molecular weight of polymer.* Journal of Pharmaceutical Sciences, 1986. 75(4): p. 356-360.
28. *Durin TM biodegradable implants. Technical information.* 2002, DURECT corporation.
29. Furr, B.J.A., and Hutchinson, F.G., *A biodegradable delivery system for peptides: preclinical experience with gonadotropin-releasing hormone agonist Zoladex®.* Journal of Controlled Release, 1991. 21: p. 117 - 128.
30. Lu, L., Garcia, C.A., and Mikos, A.G., *In vitro degradation of thin poly(DL-lactic-co-glycolic acid) films.* Journal of Biomedical Materials Research, 1999. 46(2): p. 236 - 244.
31. Lee, J.-Y., Seo, M.-H., Choi, I.-J., Kim, J.-H., and Pai, C.-M., *Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof*. 1997: United States.
32. Hsu, Y., Gresser, J.D., Trantolo, D.J., Lyons, C.M., Gangadharam, P.R.J., and Wise, D.L., *Low-density poly(DL-lactide-co-glycolide) foams for prolonged release of isoniazid.* Journal of Controlled Release, 1996. 40: p. 293 - 302.

33. Hsu, Y., Gresser, J.D., Trantolo, D.J., Lyons, C.M., Gangadharam, P.R.J., and Wise, D.L., *Effect of polymer foam morphology and density on kinetics of in vitro controlled release of isoniazid from compressed foam matrices.* Journal of Biomedical Materials Research, 1997. 35: p. 107 - 116.
34. Hsu, Y., Gresser, J.D., Stewart, R.R., Trantolo, D.J., Lyons, C.M., Simons, G.A., Gangadharam, P.R.J., and Wise, D.L., *Mechanisms of Isoniazid release from poly(d,l-lactide-co-glycolide) matrices prepared by dry-mixing and low density polymeric foam methods.* Journal of Pharmaceutical Sciences, 1996. 85(7): p. 706-713.
35. Dunn, R.L., *Biodegradable polymer composition*, in *US patent and trademark office*. 2002, Atrix laboratories: USA.
36. Tu, C., Cai, Q., Yang, J., Wan, Y., Bei, J., and Wang, S., *The fabrication and characterization of poly(lactic acid) scaffolds for tissue engineering by improved solid-liquid phase separation.* Polym. Adv. Technol., 2003. 14: p. 565 - 573.
37. Hatefi, A., and Amsden, B., *Biodegradable injectable in situ forming drug delivery systems.* Journal of Controlled Release, 2002. 80: p. 9-28.
38. Chien, Y.W., *Parenteral drug delivery and delivery systems.*, in *Novel drug delivery sytems*, Swarbrick, J, Editor. 1992, Marcel dekker, Inc.: New York. p. 381 - 528.
39. Matschke, C., Isele, U., Van Hoogevest, P., and Fahr, A., *Sustained-release injectables formed in situ and their potential use for veterinary products.* Journal of Controlled Release, 2002. 85: p. 1-15.
40. Dunn, R.L., English, J.P., Cowsar, D.R., and Vanderbilt, D.P., *In situ forming implants and methods of producing the same*. 1990: U.S.
41. Dunn, R.L., English, J.P., Cowsar, D.R., and Vanderbilt, D.D., *Biodegradable in-situ forming implants and methods of producing the same*. 1998, Atrix Laboratories, Inc.
42. Dunn, R.L., English, J.P., Cowsar, D.R., and Vanderbilt, D.D., *Biodegradable in situ forming implants*. 1997, Atrix Laboratories: U.S.
43. Shivley, M.L., Coonts, B.A., Renner, W.D., Southard, J.L., and Bennett, A.T., *Physico-chemical characterization of a polymeric injectable implant delivery system.* Journal of Controlled Release, 1995. 33: p. 237-243.

44. Dunn, R.L., Tipton, A.J., and Menardi, E.M., *A biodegradable in-situ forming drug delivery system.* Proc. Intern. Symp. Control. Rel. Bioact. Mater., 1991. 18: p. 465 - 466.
45. Lambert, W.J., and Peck, K.D., *Development of an in situ forming biodegradable poly-lactide-co-glycolide system for the controlled release of proteins.* Journal of Controlled Release, 1995. 33: p. 189 - 195.
46. Ravivarapu, H.B., Moyer, K.L., and Dunn, R.L., *Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide.* International Journal of Pharmaceutics, 2000. 194: p. 181 -191.
47. Ravivarapu, H.B., Moyer, K.L., and Dunn, R.L., *Sustained activity and release of leuprolide acetate from an in situ polymeric implant.* AAPS PharmSci Tech 2000, 2000.
48. Eliaz, R.E., and Kost, J., *Characterization of a polymeric PLGA-injectable implant delivery system for the controlled release of proteins.* Journal of Biomedical Materials Research, 2000. 50: p. 388 - 396.
49. Eliaz, R.E., and Kost, J., *Injectable system for in-situ forming solid biodegradable protein delivery.* Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 1996. 23: p. 841 - 842.
50. Ravivarapu, H.B., Moyer, K.L., and Dunn, R.L., *Sustained suppression of pituitary-gonadal axis with an injectable, in situ forming implant of leuprolide acetate.* Journal of Pharmaceutical Sciences, 2000. 89(6): p. 732-741.
51. Eliaz, R.E., Wallach, D., and Kost, J., *Delivery of Soluble Tumor Necrosis Factor Receptor from In-situ Forming PLGA Implants: In- vivo.* Pharmaceutical Research, 2000. 17(12): p. 1546 - 1550.
52. Jarr, E.M., Zhou, M., Balliu, C.M., Mitchell, J.P., Wilson, D.M., and Dunn, R.L., *Sustained release of lidocaine from an injectable implant system for treatment of post-operative pain.* Proc. Intern. Symp. Control. Rel. Bioact. Mater., 1999. 26.
53. Royals, M.A., Fujita, S.M., Yewey, G.L., Rodriguez, J., Schultheiss, P.C., and Dunn, R.L., *Biocompatibility of a biodegradable in situ forming implant system in rhesus monkeys.* Journal of Biomedical Materials Research, 1999. 45: p. 231 - 239.
54. Brodbeck, K.J., Duarte, A.G., and Shen, T., *Gel composition and methods*. 1998, Alza Corporation.

55. Chen, G., Priebe, D., Bannister, R., Baudouin, K., Wright, J., Kleiner, L., Desjardin, M., and Lucas, C., *Sustained release of a small molecule drug, bupivacaine, from alzamer® depot ™.* Proc. Intern. Symp. Control. Rel. Bioact. Mater., 2001: p. 692 - 693.

56. Brodbeck, K.J., and Shen, T., *Injectable depot gel composition and method of preparing the composition*. 1998, Alza corporation: USA.

57. Wang, L., Kleiner, L., and Venkatraman, S., *Structure formation in injectable poly(lactide-co-glycolide) depots.* Journal of Controlled Release, 2003. 90: p. 345 - 354.

58. Shah, N.H., Railkar, A.S., Chen, F.C., Tarantino, R., Kumar, S., Murjani, M., Palmer, D., Infeld, M.H., and Malick, A.W., *A biodegradable injectable implant for delivering micro and macromolecules using poly (lactic-co-glycolic) acid (PLGA) copolymers.* Journal of Controlled Release, 1993. 27: p. 139-147.

59. Graham, P.D., Brodbeck, K.J., and Mchugh, A.J., *Phase inversion dynamics of PLGA solutions related to drug delivery.* Journal of Controlled Release, 1999. 58: p. 233 - 245.

60. Desnoyer, J.R., and Mchugh, A.J., *Role of crystallization in the phase inversion dynamics and protein release kinetics of injectable drug delivery systems.* Journal of Controlled Release, 2001. 70: p. 285 - 294.

61. Brodbeck, K.J., Desnoyer, J.R., and Mchugh, A.J., *Phase inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-side mass transfer.* Journal of Controlled Release, 1999. 62: p. 333 - 344.

62. Chandrashekar, G., and Udupa, N., *Biodegradable injectable Implant systems for long term drug delivery using poly(lactic-co-glycolic) acid copolymers.* Journal Pharm. Pharmacol., 1996. 48: p. 669-674.

63. Brodbeck, K.J., Pushpala, S., and Mchugh, A.J., *Sustained release of human Growth hormone from PLGA solution depots.* Pharmaceutical Research, 1999. 16(12): p. 1825 - 1829.

64. Sullivan, S.A., Carraway, K.M., Gibson, J.W., and Tipton, A.J., *Formulation effects on controlled release of pacliataxel and other chemotherapeutic agents from a novel biodegradable system.* AAPS annual meeting abstracts, 1999. 1(4).

65. Cleland, J.L., *Injectable gels for local and systemic delivery of proteins.* Proc. Intern. Symp. Control. Rel. Bioact. Mater., 2001(#0221): p. 45-46.
66. Tripton, A.J., and Holl, R.J., *High Viscosity liquid controlled delivery system*. 1998, Southern Biosystems.
67. Ricci, E.J., Bentley, M.V.L.B., Farah, M., Bretas, R.E.S., and Marchetti, J.M., *Rheological characterization of poloxamer 407 lidocaine hydrochloride gels.* European Journal of Pharmaceutical Sciences, 2002. 17: p. 161-167.
68. Paavola, A., Yliruusi, J., and Rosenberg, P., *Controlled release and dura mater permeability of lidocaine and ibuprofen from injectable poloxamer-based gels.* Journal of Controlled Release, 1998. 52: p. 169-178.
69. Paavola, A., Tarkkila, P., Xu, M., Wahlström, T., Yliruusi, J., and Rosenberg, P., *Controlled release gel of ibuprofen and lidocaine in epidural use - Analgesia and systemic absorption in pigs.* Pharmaceutical Research, 1998. 15(3): p. 482-487.
70. Johnston, T.P., Punjabi, M.A., and Froelich, C.J., *Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice.* Pharmaceutical Research, 1992. 9(3): p. 425-434.
71. Rathi, R.C., Zentner, G.M., and Jeong, B., *Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties.*, in *U.S. patent*. 2000, Macromed, Inc.: USA.
72. Jeong, B., Choi, Y.K., Bae, Y.H., Zentner, G.M., and Kim, S.W., *New biodegradable polymers for injectable drug delivery system.* Journal of Controlled Release, 1999. 62: p. 109-114.
73. Yewey, G.L., Krinick, N.L., Dunn, R.L., Radomsky, M.L., Brouver, G., and Tripton, A.J., *Liquid delivery compositions*. 1998, Atrix Laboratories.
74. Kranz, H., Brazeau, G.A., Napaporn, J., Martin, A., Millard, W., and Bodmeier, R., *Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems.* International Journal of Pharmaceutics, 2001. 212: p. 11-18.
75. Jain, R.A., Rhodes, C.T., Railkar, A.M., Malick, A.W., and Shah, J., *Controlled delivery of drugs from a novel injectable in situ formed biodegradable PLGA microsphere system.* Journal of Microencapsulation, 2000. 17(3): p. 343-362.
76. Jain, R.A., Rhodes, C.T., Railkar, A.M., Malick, A.W., and Shah, J., *Controlled release of drugs from injectable in situ formed biodegradable PLGA*

microspheres: effect of various formulation variables. European Journal of Pharmaceutics and Biopharmaceutics, 2000. 50: p. 257-262.

77. Jain, R.A., Rodes, C.T., Railkar, A.M., Malick, A.W., and Shah, J., *Comparison of various injectable protein loaded biodegradable Poly(lactide-co-glycolide) (PLGA) Devices: In-situ formed implant versus in-situ formed microspheres versus isolated microspheres.* Pharmaceutical development and technology, 2000. 5(2): p. 201-207.
78. Tang, X., and Pikal, M.J., *Design of freeze-drying processes for pharmaceuticals: practical advice.* Pharmaceutical Research, 2004. 21(2): p. 191-200.
79. Pikal, M.J., *Freeze drying*, in *Encyclopedia of pharmaceutical technology*, Swarbrick, J, and Boylan, J C, Editors. 1992, Marcel Dekker, Inc.: New York. p. 275-303.
80. Wang, W., *Lyophilization and development of solid protein pharmaceuticals. Review.* International Journal of Pharmaceutics, 2000. 203: p. 1-60.
81. Teagarden, D.L., and Baker, D.S., *Practical aspects of lyophilization using non-aqueous co-solvent systems.* European Journal of Pharmaceutical Sciences, 2002. 15: p. 115-133.
82. Wittaya-Areekul, S., and Nail, S.L., *Freeze-drying of tert-butyl alcohol/water cosolvent systems: effects of formulation and process variables on residual solvents.* Journal of Pharmaceutical Sciences, 1998. 87(4): p. 491-495.
83. Koyama, Y., Kamat, M., Deangelis, R.J., Srinivasan, R., and Deluca, P.P., *Effect of solvent addition and thermal treatment on freeze drying of cefazolin sodium.* Journal of Parenteral Science Technology., 1988. 42(2): p. 47-52.
84. Kim, S.E., Cho, Y.W., Kang, E.J., Kwon, I.C., Lee, E.B., Kim, J.H., Chung, H., and Jeong, S.Y., *Three-dimensional porous collagen/chitosan complex sponge for tissue engineering.* Fibers and Polymers, 2001. 2(2): p. 64-70.
85. Seager, H., Taskis, C.B., Syrop, M., and Lee, T.J., *Structure of products prepared by freeze-drying solutions containing organic solvents.* Journal of Parenteral Science Technology., 1985. 39(4): p. 161-178.
86. Nam, Y.S., and Park, T.G., *Biodegradable polymeric microcellular foams by modified thermally induced phase separation method.* Biomaterials, 1999. 20: p. 1783-1790.

87. Nam, Y.S., and Park, T.G., *Porous biodegradable polymeric scaffolds prepared by thermally induced phase separation.* Journal of Biomedical Materials Research, 1999. 47(1): p. 8-17.

88. Tesconi, M.S., Sepassi, K., and Yalkowsky, S.H., *Freeze-drying above room temperature.* Journal of Pharmaceutical Sciences, 1999. 88(5): p. 501-506.

89. Deschamps, A.A., Claase, M.B., Sleijster, W.J., Bruijn, J.D., Grijpma, D.W., and Feijen, J., *Design of segmented poly(ether ester) materials and structures for the tissue engineering of bone.* Journal of Controlled Release, 2002. 78: p. 175 - 186.

90. Meredith, P., Donald, A.M., and Payne, R.S., *Freeze-drying: In situ observations using cryoenviromental scanning electron microscopy and differential scanning calorimetry.* Journal of Pharmaceutical Sciences, 1996. 85(6): p. 631-637.

91. Willemer, H., *Experimental freeze-drying: Procedures and equipment.*, in *Freeze-drying/lyophilization of pharmaceutical biological products.*, Rey, L, and May, J C, Editors. 1999, Marcel Dekker, Inc.: New York. p. 79-121.

92. Jennings, T.A., *Effect of formulation on lyophilization, part 1. Formulation components - their freezing and drying.* IVD Technology Magazine, 1997. January: p. 44-47.

93. Oesterle, J., Franks, F., and Auffret, T., *The influence of tertiary butyl alcohol and volatile salts on the sublimation of ice from frozen sucrose solutions: implications for freeze-drying.* Pharmaceutical development and technology, 1998. 3(2): p. 175-183.

94. Kovalcik, T.R., and Guillory, J.K., *The stability of cyclophosphamide in lyophilized cakes. Part I. Mannitol, lactose and sodium bicarbonate as excipients.* Journal of Parenteral Science Technology., 1988. 42(1): p. 29-37.

95. Kim, A.I., Akers, M.J., and Nail, S.L., *The physical state of mannitol after freeze-drying: effects of mannitol concentration, freezing rate, an noncrystallizing cosolute.* Journal of Pharmaceutical Sciences, 1998. 87(8): p. 931-934.

96. Zeng, X.M., Martin, G.P., and Marriot, C., *Effects of molecular weight of polyvinylpyrrolidone on the glass transition temperature and crystallization of co-lyophilized sucrose.* International Journal of Pharmaceutics, 2001. 218: p. 63-73.

97. Taylor, L.S., and Zografi, G., *Sugar-polymer hydrogen bond interactions in lyophilized amorphous mixtures.* Journal of Pharmaceutical Sciences, 1998. 87(12): p. 1615-1620.
98. Izutsu, K., Yoshioka, S., and Takeda, Y., *The effects of additives on the stability of freeze-dried ß-galactosidase stored at elevated temperature.* International Journal of Pharmaceutics, 1991. 71: p. 137-146.
99. Collagenex Pharmaceuticals, I., *AtridoxR (Doxycycline hyclate) 10%. An integral part of the successful management of chronic adult periodontitis.* 2005.
100. Sartor, O., *Eligard: leuprolide acetate in a novel sustained-release delivery system.* Urology, 2003. 61(2): p. 25-31.
101. Atrix Laboratories, I., *ELIGARD® 45 mg*. 2004, Sanofi-Synthelabo Inc.
102. Groves, M.J., *The formulation of parenteral products.*, in *Parenteral products, the preparation and quality control of products for injection.*, Ltd., W H m b, Editor. 1973: London. p. 15-47.
103. Schulz, K., *parenteral oily depot formulations. In vitro and in vivo characterization.* in *The royal Danish school of pharmacy*. 1997, The academy of technical sciences: Copenhagen.
104. Voigt, R., *Löslichkeit, Lösungsgeschwindigkeit, Löslichkeitverbesserung.*, in *Lehrbuch der pharmazeutischen Technologie.*, VCH, Editor. 1987, VEB Verlag Volk und Gesundheit.: Berlin.
105. Richards, F.H., *Solubility and dissolution rate.*, in *Pharmaceutics. The science of dosage form design.*, Aulton, M E, Editor. 1988, Churchill Livingstone: New York. p. 62-80.
106. Lachman, L., Lieberman, H.A., and Kanig, J.L., *Biopharmaceutics.*, in *The theory and practice of industrial pharmacy*, Febiger, L, Editor. 1976, Henry Kimpton publishers: Philadelphia.
107. Arwidsson, H., and Nicklasson, M., *Application of intrinsic viscosity and interaction constant as a formulation tool for film coating. I. Studies on ethyl cellulose 10 cps in organic solvents.* International Journal of Pharmaceutics, 1989. 56: p. 187-193.
108. Barton, A.F.M., *Solubility parameters.* Chemical reviews, 1975. 75(6): p. 731 - 753.
109. Martin, A., *Physical Pharmacy*. 1993, Philadelphia: Lea & Febiger.

110. *International conference on harmonization of technical requirements for registration of pharmaceuticals for human use*. 1997, ICH harmonized tripartite guideline, guideline for residual solvents.
111. Kranz, H., *In situ forming biodegradable drug delivery systems*, in *College of pharmacy*. 2000, Freie Universität Berlin: Berlin.
112. Im-Emsap, W., *In vitro and in vivo properties of injectable biodegradable in situ forming microparticle systems*, in *College of Pharmacy*. 2002, Freie Universität Berlin: Berlin. p. 292.
113. Bindschaedler, C., *Lyophilization process validation*, in *Freeze-drying/lyophilization of pharmaceutical and biological products*, Rey, L, and May, J C, Editors. 1999, Marcel Dekker, Inc.: New York. p. 373 - 408.
114. Foda, N.H., El-Laithy, H.M., and Tadros, M.I., *Optimization of biodegradable sponges as controlled release drug matrices. I. Effect of moisture level on chitosan sponge mechanical properties.* Drug Development and Industrial Pharmacy, 2004. 30(4): p. 369 - 379.
115. Zhang, R., and Ma, P.X., *Poly(alpha-hydroxyl acids)/hydroxyapatite porous composites for bone-tissue engineering. I. Preparation and Morphology.* Journal of Biomedical Materials Research, 1999. 44(4): p. 446 - 455.
116. Sachlos, E., and Czernuszka, J.T., *Making tissue engineering scaffolds work. Review on the application of solid freeform fabrication technology to the production of tissue engineering scaffolds.* European Cells and Materials, 2003. 5: p. 29 - 40.
117. Koegler, W.S., Patrick, C., Cima, M.J., and Griffith, L.G., *Carbon Dioxide Extraction of Residual Chloroform from Biodegradable Polymers.* Journal of Biomedical Materials Research, 2002. 63(5): p. 567 - 576.
118. Lai, H.L., Abu'khalil, A., and Craig, D.Q.M., *The preparation and characterization of drug-loaded alginate and chitosan sponges.* International Journal of Pharmaceutics, 2003. 251: p. 175-181.
119. Yoon, J.J., and Park, T.G., *Degradation behaviors of biodegradable macroporous scaffolds prepared by gas foaming of effervescent salts.* Journal of Biomedical Materials Research, 2001. 55(3): p. 401-408.
120. Craig, D.Q.M., *The mechanisms of drug release from solid dispersions in water-soluble polymers.* International Journal of Pharmaceutics, 2002. 231: p. 131-144.

121. Girón, D., *Encyclopedia of pharmaceutical technology.*, in *Thermal analysis of drugs and drug products*, James Swarbrick, J c B, Editor. 1997, Marcel Dekker: New York. p. 79.
122. Chen, P., Park, Y.J., Chang, L., Kohane, D., Bartlett, R.H., Langer, R., and Yang, V.C., *Injectable microparticle-gel system for prolonged and localized lidocaine release. I. In vitro characterization.* Journal of Biomedical materials, 2004. 70A(3): p. 412-419.
123. Lin, W., Flanagan, D.R., and Linhardt, R., *Accelerated degradation of poly(ε-caprolactone) by organic amines.* Pharmaceutical Research, 1994. 11(7): p. 1030 - 1034.
124. Mauduit, J., Bukh, N., and Vert, M., *Gentamycin/poly(lactic acid) blends aimed at sustained release local antibiotic therapy administered per-operatively. I. The case of gentamycin base and gentamycin sulfate in poly(DL-lactic acid) oligomers.* Journal of Controlled Release, 1993. 23: p. 209 - 220.
125. Park, T.G., *Degradation of poly(lactic-co-glycolic acid) microspheres: effect of copolymer composition.* Biomaterials, 1995. 16: p. 1123-1130.
126. Mauduit, J., Bukh, N., and Vert, M., *Gentamycin/poly(lactic acid) blends aimed at sustained release local antibiotic therapy administered per-operatively. II. The case of gentamycin sulfate in high molecular weight poly(DL-lactic acid) and poly(L-lactic acid).* Journal of Controlled Release, 1993. 23: p. 221 - 230.
127. Serajuddin, A.T.M., *Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs.* Journal of Pharmaceutical Sciences, 1999. 88(10): p. 1058 - 1066.